HER-2 expression
HER-2 expression
|
Endometrial Adenocarcinoma
Endometrial Adenocarcinoma
|
trastuzumab
Sensitive: A2 - Guideline
|
HER-2 expression
HER-2 expression
|
Breast Cancer
Breast Cancer
|
ARX788
Sensitive: B - Late Trials
|
HER-2 expression
HER-2 expression
|
Biliary Tract Cancer
Biliary Tract Cancer
|
ZW25
Sensitive: B - Late Trials
|
HER-2 expression
HER-2 expression
|
Cholangiocarcinoma
Cholangiocarcinoma
|
trastuzumab + lapatinib
Sensitive: B - Late Trials
|
HER-2 expression
HER-2 expression
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
trastuzumab + pertuzumab
Sensitive: C2 – Inclusion Criteria
|
HER-2 expression
HER-2 expression
|
Gastric Cancer
Gastric Cancer
|
trastuzumab
Sensitive: C2 – Inclusion Criteria
|
HER-2 expression
HER-2 expression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki
Sensitive: C2 – Inclusion Criteria
|
HER-2 expression
HER-2 expression
|
Gastric Cancer
Gastric Cancer
|
A166
Sensitive: C2 – Inclusion Criteria
|
HER-2 expression
HER-2 expression
|
Breast Cancer
Breast Cancer
|
lapatinib
Sensitive: C2 – Inclusion Criteria
|
HER-2 expression
HER-2 expression
|
|
A166
Sensitive: C2 – Inclusion Criteria
|
HER-2 expression
HER-2 expression
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
A166
Sensitive: C2 – Inclusion Criteria
|
HER-2 expression
HER-2 expression
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
avelumab
Sensitive: C2 – Inclusion Criteria
|
HER-2 expression
HER-2 expression
|
|
fam-trastuzumab deruxtecan-nxki
Sensitive: C2 – Inclusion Criteria
|
HER-2 expression
HER-2 expression
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
ZW25
Sensitive: C3 – Early Trials
|
HER-2 expression
HER-2 expression
|
Salivary Gland Cancer
Salivary Gland Cancer
|
ARX788
Sensitive: C3 – Early Trials
|
HER-2 expression
HER-2 expression
|
|
ARX788
Sensitive: C3 – Early Trials
|
HER-2 expression
HER-2 expression
|
Biliary Tract Cancer
Biliary Tract Cancer
|
ARX788
Sensitive: C3 – Early Trials
|
HER-2 expression
HER-2 expression
|
Non Small Cell Lung Cancer
NSCLC
|
ARX788
Sensitive: C3 – Early Trials
|
HER-2 expression
HER-2 expression
|
Gastric Cancer
Gastric Cancer
|
ARX788
Sensitive: C3 – Early Trials
|
HER-2 expression
HER-2 expression
|
|
panitumumab
Resistant: C3 – Early Trials
|
HER-2 expression
HER-2 expression
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
nivolumab + fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
|
HER-2 expression
HER-2 expression
|
|
fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
|
HER-2 expression
HER-2 expression
|
Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma
|
trastuzumab + erlotinib + gemcitabine
Sensitive: C3 – Early Trials
|
HER-2 expression
HER-2 expression
|
|
trastuzumab + lapatinib
Sensitive: C3 – Early Trials
|
HER-2 expression
HER-2 expression
|
Childhood B Acute Lymphoblastic Leukemia
Childhood B Acute Lymphoblastic Leukemia
|
trastuzumab
Resistant: C3 – Early Trials
|
HER-2 expression
HER-2 expression
|
Endometrial Cancer
Endometrial Cancer
|
fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
|
HER-2 expression
HER-2 expression
|
Gastrointestinal Cancer
Gastrointestinal Cancer
|
pembrolizumab + margetuximab
Sensitive: C3 – Early Trials
|
HER-2 expression
HER-2 expression
|
Salivary Gland Cancer
Salivary Gland Cancer
|
fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
|
HER-2 expression
HER-2 expression
|
|
cetuximab
Sensitive: C3 – Early Trials
|
HER-2 expression
HER-2 expression
|
Urothelial Cancer
Urothelial Cancer
|
toripalimab + RC48
Sensitive: C3 – Early Trials
|
HER-2 expression
HER-2 expression
|
|
trastuzumab + tucatinib
Sensitive: D – Preclinical
|
HER-2 expression
HER-2 expression
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
paclitaxel
Sensitive: D – Preclinical
|
HER-2 expression
HER-2 expression
|
|
tucatinib
Sensitive: D – Preclinical
|
HER-2 expression
HER-2 expression
|
Pancreatic Cancer
Pancreatic Cancer
|
afatinib
Sensitive: D – Preclinical
|
